| ID | 1332 |
| Name of the vaccine | Vi-rEPA |
| Microbe | Bacteria |
| Disease name | Typhoid |
| Name of bacteria | Salmonella typhi |
| Type of vaccine | Conjugate |
| Nucleic acid content | DNA |
| Age | Child, adult, older adult |
| Description of the vaccine | Conjugate vaccine for Typhoid fever. |
| Name of the manufacturer | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
| Name of the manufacturing country | Vietnam |
| Year of manufacture | 2011 |
| Clinical Phase status | Clinical - Phase 2 |
| Bacterial strain | Gram negative bacteria |
| Efficacy | NA |
| Vaccine formulation | NA |
| Dosage | Three doses at 2, 4, and 6 months. Booster dose at 12 months of age. |
| Mechanism of action | Elicited serum IgG anti-Vi. |
| Route of administration | NA |
| Indications | NA |
| Export | NA |
| Approval | NA |
| Adjuvant | NA |
| Repurposing | NA |
| Side effects of vaccine | NA |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NCT00342628 |
| Reference | NA |
| Other name | NA |
| Additional Links | NA
|